These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 30408848)

  • 21. Phase 3 Trial of Concizumab in Hemophilia with Inhibitors.
    Matsushita T; Shapiro A; Abraham A; Angchaisuksiri P; Castaman G; Cepo K; d'Oiron R; Frei-Jones M; Goh AS; Haaning J; Hald Jacobsen S; Mahlangu J; Mathias M; Nogami K; Skovgaard Rasmussen J; Stasyshyn O; Tran H; Vilchevska K; Villarreal Martinez L; Windyga J; You CW; Zozulya N; Zulfikar B; Jiménez-Yuste V;
    N Engl J Med; 2023 Aug; 389(9):783-794. PubMed ID: 37646676
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Befovacimab, an anti-tissue factor pathway inhibitor antibody: Early termination of the multiple-dose, dose-escalating Phase 2 study due to thrombosis.
    Mancuso ME; Ingham SJM; Kunze M
    Haemophilia; 2022 Sep; 28(5):702-712. PubMed ID: 35667016
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concizumab improves clot formation in hemophilia A under flow.
    Jewell MP; Ashour Z; Baird CH; Manco Johnson M; Warren BB; Wufsus AR; Pallini C; Dockal M; Kjalke M; Neeves KB
    J Thromb Haemost; 2024 Sep; 22(9):2438-2448. PubMed ID: 38815755
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The pharmacokinetics and pharmacodynamics of single-dose and multiple-dose recombinant activated factor VII in patients with haemophilia A or B.
    Fernández-Bello I; Stenmo C; Butta N; Lind V; Ezban M; Jiménez-Yuste V
    Haemophilia; 2017 Nov; 23(6):868-876. PubMed ID: 28851065
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tissue factor pathway inhibitor is the main determinant of thrombin generation in haemophilic patients.
    Chelle P; Montmartin A; Damien P; Piot M; Cournil M; Lienhart A; Genre-Volot F; Chambost H; Morin C; Tardy-Poncet B
    Haemophilia; 2019 Mar; 25(2):343-348. PubMed ID: 30690836
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant human prothrombin (MEDI8111) prevents bleeding in haemophilia A and B mice.
    Hansson KM; Lindblom A; Elg M; Lövgren A
    Haemophilia; 2016 May; 22(3):453-61. PubMed ID: 26635073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Concizumab as a Subcutaneous Prophylactic Treatment Option for Patients with Hemophilia A or B: A Review of the Evidence and Patient's Perspectives.
    Pasca S
    J Blood Med; 2022; 13():191-199. PubMed ID: 35465188
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase 1b/2 clinical study of marstacimab, targeting human tissue factor pathway inhibitor, in haemophilia.
    Mahlangu JN; Lamas JL; Morales JC; Malan DR; Šalek SZ; Wang M; Boggio LN; Hegemann I; Mital A; Cardinal M; Zhu T; Sun P; Arkin S
    Br J Haematol; 2023 Jan; 200(2):229-239. PubMed ID: 35999026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Concizumab promotes haemostasis via a tissue factor-factor VIIa-dependent mechanism supporting prophylactic treatment of haemophilia: Results from a rabbit haemophilia bleeding model.
    Lauritzen B; Hilden I
    Haemophilia; 2019 Nov; 25(6):e379-e382. PubMed ID: 31609513
    [No Abstract]   [Full Text] [Related]  

  • 30. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study.
    Pipe SW; Shima M; Lehle M; Shapiro A; Chebon S; Fukutake K; Key NS; Portron A; Schmitt C; Podolak-Dawidziak M; Selak Bienz N; Hermans C; Campinha-Bacote A; Kiialainen A; Peerlinck K; Levy GG; Jiménez-Yuste V
    Lancet Haematol; 2019 Jun; 6(6):e295-e305. PubMed ID: 31003963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanistic Modeling of the Pharmacodynamic and Pharmacokinetic Relationship of Tissue Factor Pathway Inhibitor-Neutralizing Antibody (BAY 1093884) in Cynomolgus Monkeys.
    Gu JM; Zhao XY; Schwarz T; Schuhmacher J; Baumann A; Ho E; Subramanyan B; Tran K; Myles T; Patel C; Koellnberger M
    AAPS J; 2017 Jul; 19(4):1186-1195. PubMed ID: 28516358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The potential role of synovial thrombomodulin in the pathophysiology of joint bleeds in haemophilia.
    Dargaud Y; Simpson H; Chevalier Y; Scoazec JY; Hot A; Guyen O; Baglin T; Négrier C
    Haemophilia; 2012 Sep; 18(5):818-23. PubMed ID: 22533488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pro- and anticoagulant factors facilitate thrombin generation and balance the haemostatic response to FEIBA(®) in prophylactic therapy.
    Varadi K; Tangada S; Loeschberger M; Montsch P; Schrenk G; Ewenstein B; Turecek PL
    Haemophilia; 2016 Jul; 22(4):615-24. PubMed ID: 26879158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia.
    Chowdary P
    Int J Hematol; 2020 Jan; 111(1):42-50. PubMed ID: 30302740
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progress in the Development of Anti-tissue Factor Pathway Inhibitors for Haemophilia Management.
    Mahlangu JN
    Front Med (Lausanne); 2021; 8():670526. PubMed ID: 34026796
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hemostatic properties of a TFPI antibody.
    Petersen LC
    Thromb Res; 2012 May; 129 Suppl 2():S44-5. PubMed ID: 22405586
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and dose-dependency of eptacog beta (activated) in a dose escalation study of non-bleeding congenital haemophilia A or B patients, with or without inhibitors.
    Ducore J; Lawrence JB; Simpson M; Boggio L; Bellon A; Burggraaf J; Stevens J; Moerland M; Frieling J; Reijers J; Wang M
    Haemophilia; 2017 Nov; 23(6):844-851. PubMed ID: 28984010
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO.
    Collins P; Chalmers E; Chowdary P; Keeling D; Mathias M; O'Donnell J; Pasi KJ; Rangarajan S; Thomas A
    Haemophilia; 2016 Jul; 22(4):487-98. PubMed ID: 27311929
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dosing regimens, FVIII levels and estimated haemostatic protection with special focus on rFVIIIFc.
    Berntorp E; Negrier C; Gozzi P; Blaas PM; Lethagen S
    Haemophilia; 2016 May; 22(3):389-96. PubMed ID: 26863900
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paradigm shift for the treatment of hereditary haemophilia: Towards precision medicine.
    Spadarella G; Di Minno A; Milan G; Franco N; Polimeno M; Castaldo F; Di Minno G
    Blood Rev; 2020 Jan; 39():100618. PubMed ID: 31676141
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.